Multivalent Inactivated Vaccine Protects Chickens from Distinct Clades of Highly Pathogenic Avian Influenza Subtypes H5N1 and H5N8.

IF 5.2 3区 医学 Q1 IMMUNOLOGY Vaccines Pub Date : 2025-02-19 DOI:10.3390/vaccines13020204
Walid H Kilany, Marwa Safwat, Mohamed A Zain El-Abideen, Islam Hisham, Yasmine Moussa, Ahmed Ali, Magdy F Elkady
{"title":"Multivalent Inactivated Vaccine Protects Chickens from Distinct Clades of Highly Pathogenic Avian Influenza Subtypes H5N1 and H5N8.","authors":"Walid H Kilany, Marwa Safwat, Mohamed A Zain El-Abideen, Islam Hisham, Yasmine Moussa, Ahmed Ali, Magdy F Elkady","doi":"10.3390/vaccines13020204","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/objective: </strong>Highly pathogenic avian influenza (HPAI) H5 subtype remains a significant menace to both the poultry industry and human public health. Biosecurity and mass vaccination of susceptible commercial poultry flocks are crucial to reduce the devastating economic loss and hinder the evolution of the virus.</p><p><strong>Methods: </strong>In this study, we developed a multivalent avian influenza virus (AIV) vaccine, including strains representing the HPAI 2.2.1.1., 2.2.1.2., and 2.3.4.4b clades circulating in Egypt and the Middle East. Specific pathogen-free (SPF) two-week-old chickens were vaccinated with a single vaccine shot and observed for four weeks post-vaccination before being challenged. The challenge experiment involved using one strain of HPAI H5N1 subtype clade 2.2.1.2 and two strains of HPAI H5N8 subtype clade 2.3.4.4b derived from chickens and ducks. To assess the vaccine's potency and efficacy, the pre-challenge humoral immune response and post-challenge survival and virus shedding were evaluated. <b>Results:</b> All the vaccinated birds exhibited 100% seroconversion 2 weeks post-vaccination (2 WPV). In addition, protective antibody titers against each diagnostic antigen, i.e., 7.8 ± 1.8 (H5N1, clade 2.2.1.2), 10.0 ± 0.0 (H5N1, clade 2.2.1.1), and 7.5 ± 0.9 (H5N8, clade 2.3.4.4b) were detected 3 WPV. The vaccination achieved complete protection (100%) against all challenge viruses with no disease symptoms. The vaccinated birds exhibited a statistically significant reduction in oropharyngeal virus shedding 2 days post-challenge (DPC).</p><p><strong>Conclusions: </strong>This study illustrated that a single application of a multivalent genetic-matching whole AIV vaccine under laboratory conditions elicits adequate protection against the HPAI challenge, representing 2.2.1.2 and 2.3.4.4b clades. The developed vaccine has the potential to be a vaccine of choice against a broad range of HPAI in commercial flocks raised under field conditions in endemic areas.</p>","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"13 2","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11860572/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/vaccines13020204","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background/objective: Highly pathogenic avian influenza (HPAI) H5 subtype remains a significant menace to both the poultry industry and human public health. Biosecurity and mass vaccination of susceptible commercial poultry flocks are crucial to reduce the devastating economic loss and hinder the evolution of the virus.

Methods: In this study, we developed a multivalent avian influenza virus (AIV) vaccine, including strains representing the HPAI 2.2.1.1., 2.2.1.2., and 2.3.4.4b clades circulating in Egypt and the Middle East. Specific pathogen-free (SPF) two-week-old chickens were vaccinated with a single vaccine shot and observed for four weeks post-vaccination before being challenged. The challenge experiment involved using one strain of HPAI H5N1 subtype clade 2.2.1.2 and two strains of HPAI H5N8 subtype clade 2.3.4.4b derived from chickens and ducks. To assess the vaccine's potency and efficacy, the pre-challenge humoral immune response and post-challenge survival and virus shedding were evaluated. Results: All the vaccinated birds exhibited 100% seroconversion 2 weeks post-vaccination (2 WPV). In addition, protective antibody titers against each diagnostic antigen, i.e., 7.8 ± 1.8 (H5N1, clade 2.2.1.2), 10.0 ± 0.0 (H5N1, clade 2.2.1.1), and 7.5 ± 0.9 (H5N8, clade 2.3.4.4b) were detected 3 WPV. The vaccination achieved complete protection (100%) against all challenge viruses with no disease symptoms. The vaccinated birds exhibited a statistically significant reduction in oropharyngeal virus shedding 2 days post-challenge (DPC).

Conclusions: This study illustrated that a single application of a multivalent genetic-matching whole AIV vaccine under laboratory conditions elicits adequate protection against the HPAI challenge, representing 2.2.1.2 and 2.3.4.4b clades. The developed vaccine has the potential to be a vaccine of choice against a broad range of HPAI in commercial flocks raised under field conditions in endemic areas.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
多价灭活疫苗保护鸡免受H5N1和H5N8高致病性禽流感不同分支的感染。
背景/目的:高致病性禽流感(HPAI) H5亚型仍然是对家禽业和人类公共卫生的重大威胁。生物安全和对易感商业禽群进行大规模疫苗接种对于减少破坏性经济损失和阻碍病毒演变至关重要。方法:本研究研制了一种多价禽流感病毒(AIV)疫苗,包括HPAI 2.2.1.1毒株。2.2.1.2。,以及在埃及和中东传播的2.3.4.4b分支。对两周龄的无特定病原体(SPF)鸡接种单针疫苗,并在接种后观察四周,然后再进行攻毒。攻毒实验采用来自鸡鸭的1株高致病性H5N1亚型进化枝2.2.1.2和2株高致病性H5N8亚型进化枝2.3.4.4b。为了评估疫苗的效力和有效性,我们评估了攻击前的体液免疫反应和攻击后的存活和病毒脱落。结果:接种疫苗后2周(2 WPV)所有禽类血清转化均为100%。此外,检测到各诊断抗原的保护性抗体滴度分别为7.8±1.8 (H5N1,分支2.2.1.2)、10.0±0.0 (H5N1,分支2.2.1.1)和7.5±0.9 (H5N8,分支2.3.4.4b)。疫苗接种实现了对所有挑战病毒的完全保护(100%),没有疾病症状。接种疫苗的禽类在攻毒后2天的口咽病毒脱落(DPC)有统计学意义的显著减少。结论:本研究表明,在实验室条件下,单次应用一种多价基因匹配的全AIV疫苗,就能对2.2.1.2和2.3.4.4b进化支的高致病性禽流感病毒产生足够的保护。开发的疫苗有可能成为在流行地区野外条件下饲养的商业禽群中防治各种高致病性禽流感的首选疫苗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Vaccines
Vaccines Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
8.90
自引率
16.70%
发文量
1853
审稿时长
18.06 days
期刊介绍: Vaccines (ISSN 2076-393X) is an international, peer-reviewed open access journal focused on laboratory and clinical vaccine research, utilization and immunization. Vaccines publishes high quality reviews, regular research papers, communications and case reports.
期刊最新文献
Virus-like and Virus Replicon Particles Targeting Multiple B-Cell Antigens Do Not Protect Against African Swine Fever Virus. Lambda Phage-Based Antibody-Stimulating Platform Targeting EGFRvIII. Structural Design of T-Cell Epitope-Based mRNA Vaccine Constructs Determines the Quality of T-Cell Immunity and Protective Efficacy Against SARS-CoV-2 in Mice. Baseline Hepatitis B Immunity and Vaccination Booster Response Among Medical Residents: A Longitudinal Study in a Spanish Tertiary Hospital. SARS-CoV-2 and Influenza Co-Circulation and Co-Vaccination: A Narrative Review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1